The specter of generic challenges has repeatedly loomed around copyright’s iconic drug, PDE5 Inhibitor, triggering questions about the outlook of related medicinal holdings. While early periods saw impressive gains, the patent lapse has opened the path for less expensive copies, potentially reducing revenue and creating a real risk for stakehold… Read More